Cheryl Zigrand

The data being amassed about novel multiple myeloma therapies have the potential to change the way patients with relapsed or refractory disease are currently being treated.

When Bernard Fisher, MD, first became involved in breast cancer research, the only treatment option available to patients was the radical mastectomy, a horribly disfiguring surgery that had been the undisputed standard of care since the late 1800s